Omnicell, Inc. (NASDAQ:OMCL) Receives $47.83 Average PT from Brokerages

Omnicell, Inc. (NASDAQ:OMCL) has been given an average rating of “Hold” by the eight analysts that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $47.8333.

A number of equities analysts have recently weighed in on the company. Benchmark upped their target price on Omnicell from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Wells Fargo & Company upped their price objective on shares of Omnicell from $43.00 to $52.00 and gave the stock an “overweight” rating in a report on Monday, January 5th. KeyCorp upgraded shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price objective for the company in a report on Wednesday, January 7th. Weiss Ratings restated a “sell (d+)” rating on shares of Omnicell in a report on Wednesday, October 8th. Finally, Zacks Research cut shares of Omnicell from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 9th.

Omnicell Stock Up 0.9%

OMCL stock opened at $51.19 on Thursday. The stock’s 50 day simple moving average is $41.42 and its 200 day simple moving average is $34.48. The company has a market cap of $2.30 billion, a P/E ratio of 119.05, a price-to-earnings-growth ratio of 5.40 and a beta of 0.77. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.21 and a current ratio of 1.44. Omnicell has a fifty-two week low of $22.66 and a fifty-two week high of $51.30.

Insider Activity

In related news, EVP Corey J. Manley sold 6,106 shares of the company’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $49.90, for a total transaction of $304,689.40. Following the completion of the sale, the executive vice president owned 91,674 shares in the company, valued at approximately $4,574,532.60. This represents a 6.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 2.52% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Omnicell

A number of hedge funds have recently bought and sold shares of OMCL. Dimensional Fund Advisors LP raised its holdings in shares of Omnicell by 9.1% in the third quarter. Dimensional Fund Advisors LP now owns 2,364,068 shares of the company’s stock valued at $71,985,000 after purchasing an additional 197,462 shares during the last quarter. Lazard Asset Management LLC increased its stake in Omnicell by 3.8% in the 2nd quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock valued at $50,225,000 after buying an additional 62,733 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Omnicell by 1.3% during the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,423,604 shares of the company’s stock worth $41,854,000 after buying an additional 17,680 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Omnicell by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 1,195,896 shares of the company’s stock worth $35,163,000 after buying an additional 30,678 shares during the last quarter. Finally, Millennium Management LLC bought a new position in shares of Omnicell in the third quarter valued at approximately $25,625,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.